ArticleAmerican journal of translational research2025
The effect of an intravenous analgesic pump with esketamine on postoperative pain and postpartum depression in women with cesarean section.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of hydromorphone for patient-controlled intravenous analgesia on postpartum depression and sleep disorders after cesarean section: a randomized, double-blind controlled trial.Frontiers in pharmacology · 2026Trial
- Effect of Subanesthetic Doses of Esketamine on Early Postoperative Pain Sensitivity in Patients Undergoing Salpingectomy: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Esketamine relieves postoperative depression and pain indicators in patients undergoing laparoscopic total hysterectomy.BMC anesthesiology · 2025Trial
- Case Report: Nursing strategies for colon cancer surgery in third-trimester pregnancy.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the efficacy of an intravenous analgesic pump containing esketamine for postoperative pain relief and its impact on postpartum depression in women undergoing cesarean sections.
methodsA retrospective analysis was conducted on 147 women who underwent cesarean deliveries at Xiamen Hospital of Traditional Chinese Medicine from April 2022 to May 2024. Based on different pain management protocols, the participants were divided into two groups: the observation group (n=81) and the control group (n=66). The observation group received intravenous esketamine post-delivery, followed by postoperative analgesia using a pain pump with esketamine and Sufentanil. Various outcomes were assessed, including Visual Analog Scale (VAS) pain scores, Edinburgh Postnatal Depression Scale (EPDS) scores, and serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), cortisol (Cor), and brain-derived neurotrophic factor (BDNF).
resultsAt 12, 24, and 48 hours post-surgery, VAS pain scores (both resting and coughing) were significantly lower in the observation group compared to the control group (P<0.05). EPDS scores were significantly higher at 3, 7, and 42 days post-surgery in both groups compared to pre-surgery levels (P<0.05), with the observation group exhibiting significantly lower EPDS scores at 3 and 7 days (P<0.05). Serum levels of IL-6, TNF-α, and Cor were significantly reduced at 24 and 48 hours post-surgery in both groups, while BDNF levels were significantly elevated (P<0.05). At 24 and 48 hours, the observation group had significantly lower levels of IL-6, TNF-α, and Cor, along with higher BDNF levels, compared to the control group (P<0.05). No significant differences in adverse reactions were observed between the two groups (P>0.05).
conclusionEsketamine-based postoperative analgesia for cesarean section effectively reduces perioperative pain, alleviates postpartum depression, mitigates inflammatory and stress responses, and has certain neuroprotective effects. Its safety profile supports its potential for broader clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.